Connect your AI

Alamar Biosciences ALMR Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

T-Mobile USTMUS

$61M-23.8%

Rocket Lab USA, Inc.RKLB

$13.43M+721%

Northrop GrummanNOC

$551M-48.5%

Bloom EnergyBE

$64.69M+4,292%

Ionis PharmaceuticalsIONS

$7.63M+115%

GE HealthCare TechnologiesGEHC

$46M+188%

Other financials

Income statement

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's increase (decrease) in contract with customer, asset.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alamar Biosciences 's increase (decrease) in contract with customer, asset?: Alamar Biosciences (ALMR) reported increase (decrease) in contract with customer, asset of -$282K in Q1 2025.